1,928 results on '"Zile, Michael R."'
Search Results
2. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to
3. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
4. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
5. Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
6. A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor
7. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
8. Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension
9. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
10. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
11. Abstract 16755: Changes in Mid-Regional Pro-Adrenomedullin During Treatment With Sacubitril/Valsartan
12. Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
13. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF
14. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial
15. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
16. Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides
17. Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure
18. Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure
19. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
20. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
21. Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes
22. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
23. In vivo fluid dynamics of the Ventura interatrial shunt device in patients with heart failure
24. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis
25. Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum: The GUIDE-HF Trial
26. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
27. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF
28. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
29. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
30. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes
31. Interatrial shunt therapy in advanced heart failure: Outcomes from the open‐label cohort of the RELIEVE‐HF trial
32. 426 A Beat Away from Precision Medicine: Characterizing Human Cardiac Fibroblast Responsiveness to Hemodynamic Unloading in Heart Failure with Reduced Ejection Fraction
33. In Memoriam—William H. Gaasch, MD, 1937-2022
34. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study
35. Role of Macrophages in Regression of Myocardial Fibrosis Following Alleviation of Left Ventricular Pressure Overload
36. Left ventricle function and post-transcriptional events with exercise training in pigs
37. Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction
38. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
39. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
40. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
41. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion
42. Incidence and Outcomes of Pneumonia in Patients With Heart Failure
43. Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?
44. Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction
45. Independent prognostic importance of blood urea nitrogen to creatinine ratio in heart failure
46. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF.
47. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation
48. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
49. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials
50. Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.